CN Stock MarketDetailed Quotes

Xizang Weixinkang Pharmaceutical (603676)

Watchlist
  • 11.11
  • -0.04-0.36%
Market Closed Jan 16 15:00 CST
4.83BMarket Cap21.78P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Xizang Weixinkang Pharmaceutical (603676) Revenue Breakdown Overview

By Product

Currency:CNY
2025/H1
Stock NameRevenueRatio
市场服务其他422.51M72.08%
Drugs163.67M27.92%

By Industry

Currency:CNY
2025/H1
Stock NameRevenueRatio
市场服务及其他422.51M72.08%
Drug income163.67M27.92%

By Country/Region

Currency:CNY
2025/H1
Stock NameRevenueRatio
Central China133.85M22.84%
East China region122.76M20.94%
North China119.51M20.39%
Southwest area76.82M13.11%
South China71.4M12.18%
Northeast area34.26M5.84%
Northwest region27.58M4.70%
View all

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
HK Tech and Internet Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +17.85%
Sample Name
Sample Code
 +16.38%
Sample Name
Sample Code
 +13.45%
4
BIDU-SW
09888
+5.97%
5
JD HEALTH
06618
+5.25%
View More
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +3.11%
Sample Name
Sample Code
 +2.53%
Sample Name
Sample Code
 +2.08%
4
Tempus AI
TEM
+2.05%
5
Block
XYZ
+1.59%
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -